SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

Voranigo

RPRX·Royalty Pharma plc
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed. FDA approval was August 6, 2024; EMA approval was September 17, 2025.
Why 4/10
Voranigo is already approved and commercialized with no pending regulatory decision or pivotal readout scheduled. As a royalty asset for RPRX, its contribution to share price is gradual through quarterly sales growth, not a binary catalyst. The next hard catalyst for RPRX (neladalkib PDUFA on November 27, 2026) is a different drug. ImpactScore is 4 per the rubric for an approved drug with no imminent binary event.
Actionable Insight NEUTRAL

Voranigo has no pending binary catalyst. Investors should track Servier's commercial execution and quarterly royalty receipts reported by RPRX. RPRX's next major catalyst is the November 27, 2026 PDUFA for neladalkib (a different drug), which is unrelated to Voranigo. Voranigo's contribution to RPRX's value will unfold gradually through sales growth and market expansion across its approved territories.

Price Chart

Loading chart...

Executive Summary

Voranigo (vorasidenib) is an FDA- and EMA-approved oral targeted therapy for Grade 2 IDH-mutant glioma, developed and marketed by private French company Servier. Royalty Pharma (RPRX) owns the royalty rights, having paid Agios Pharmaceuticals $905 million upfront for a 15% royalty on U.S. net sales up to $1 billion (12% above $1 billion). The drug is already generating revenue for RPRX (cited as a growth driver in Q3 2026 earnings) with peak sales estimated above $1 billion. There is no pending binary catalyst for this drug; its impact on RPRX's stock is gradual through commercial execution rather than a single event.

How It Works

Voranigo is a once-daily pill that blocks two mutant enzymes, IDH1 and IDH2, found in certain slow-growing brain tumors (Grade 2 gliomas). By inhibiting these enzymes, it reduces the production of a cancer-promoting metabolite called 2-HG, which can slow or stop tumor growth. It is the first targeted therapy (not chemotherapy or radiation) approved for this specific type of brain cancer.

Trial Status

Voranigo was approved by the FDA on August 6, 2024, based on the pivotal Phase 3 INDIGO trial, which showed a significant improvement in progression-free survival (median 27.7 months vs. 11.1 months for placebo). The European Commission approved it on September 17, 2025. At ASCO 2026, Servier presented extended follow-up data (over three years) showing median progression-free survival of 44.1 months, confirming durable benefit. The drug is now approved in over 40 countries.

The Two-Sided Case

▲ Bull Case5
First and only FDA-approved targeted therapy for Grade 2 IDH-mutant glioma, addressing a clear unmet need with no direct competition.
Phase 3 INDIGO data showed compelling efficacy (median PFS 27.7 months vs. 11.1 months for placebo), and extended follow-up at ASCO 2026 showed median PFS of 44.1 months, reinforcing durable benefit.
Royalty Pharma projects peak annual sales above $1 billion, which would generate over $150 million in annual royalty revenue for RPRX at the 15% rate.
Voranigo was cited as a key growth driver in RPRX's Q3 2026 earnings, with Royalty Receipts up 9% year-over-year, and the company raised full-year guidance for the third consecutive time.
Approved in over 40 countries including the EU and Japan, expanding the addressable market beyond the U.S.
▼ Bear Case5
Royalty Pharma is not the developer or marketer of Voranigo; it only holds a royalty interest. It has no control over Servier's pricing, commercialization, or manufacturing.
The addressable patient population is narrow (Grade 2 IDH-mutant glioma), which may limit peak sales potential despite high per-patient pricing.
NICE draft guidance in the UK (March 2026) recommends Voranigo for NHS use, but reimbursement negotiations and market access in Europe could affect the pace of uptake.
Royalty Pharma paid $905 million upfront for the royalty stream, a large upfront commitment that requires years of sales to earn a return on investment.
The drug's NCE-1 exclusivity runs until August 2028, after which generic competition could erode the royalty stream.

Upcoming Catalysts

  • No pending regulatory decision for Voranigo specifically. Royalty Pharma's next PDUFA date (November 27, 2026) is for a different drug, neladalkib. Continued commercial uptake and quarterly royalty receipts are the ongoing drivers.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Royalty Pharma plc PRESS-RELEASE RPRX ·Originating report

Sources · 10

Hover a chip for the title
1 fda.gov2 servier.us3 royaltypharma.com4 servier.mediaroom.com5 servier.mediaroom.com6 markets.financialcontent.com7 fiscal.ai8 sec.gov9 royaltypharma.com10 servier.co.uk